Potential Conflicts of Interest.
All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
REFERENCES
  1. Goetz D and Ren CL. Review of Cystic Fibrosis. Pediatric Annals. 2019;48(4):e154-e161.
  2. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry . 2011 Annual Data Report. Bethesda, Maryland, 2018.
  3. Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med . 2009 Nov 1;180(9):802-8.
  4. Döring G, Flume P, Heijerman H, et al. Treatment of lung infection in patients with cystic fibrosis: Current and future strategies. Journal of Cystic Fibrosis. 2012. 11(6): 461-479.
  5. Lim S, Fitzgerald D. Treatment resistant Pseudomonas aeruginosa lung disease in young children with cystic fibrosis. Paediatric Respiratory Reviews. 2018 (27): 33-36.
  6. Winstanley C, O’Brien A, Brockhurst MA. Pseudomonas aeruginosa Evolutionary Adaptation and Diversification in Cystic Fibrosis Chronic Lung Infections. Trends in Microbiology. 2016. 24 (5): 327-337.
  7. Stefani S, et al. Relevance of multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis. Int J Med Microbiol. 2017: 307(6): 353-362.
  8. De Sutter P, Gasthuys E, Van Braeckel E et al. Pharmacokinetics in Patients with Cystic Fibrosis: A Systematic Review of Data Published Between 1999 and 2019. Clin Pharmacokinet (2020).
  9. Konold V, et al. Comparison of Population-Specific Cystic Fibrosis Antibiograms Versus Hospital-Wide Antibiograms for Two Cystic Fibrosis Centers. Open Forum Infectious Diseases . 2016;3(1):682.
  10. Hindler JF and Stelling J. Analysis and Presentation of Cumulative Antibiograms: A New Consensus Guideline from the Clinical and Laboratory Standards Institute. Clinical Infectious Diseases 2007; 44:867–73.
  11. Eyns H, Piérard D, De Wachter E, et al. Respiratory Bacterial Culture Sampling in Expectorating and Non-expectorating Patients With Cystic Fibrosis. Front Pediatr. 2018;6:403.
  12. Seidler D, Griffin M, Nymon A, et al. Throat Swabs and Sputum Culture as Predictors of P. aeruginosa or S. aureus Lung Colonization in Adult Cystic Fibrosis Patients. PLoS ONE. 2016;11(10): e0164232.
  13. Mogayzel PJ, Naureckas ET, Robinson KA, et al. Cystic Fibrosis Foundation Pulmonary Guideline: Pharmacologic Approaches to Prevention and Eradication of Pseudomonas aeruginosa Infection. Ann Am Thorac Soc. 2014; 11(10): 1640-1650.
  14. Prevaes SM, de Steenhuijsen Piters WA, de Winter-de Groot KM, et al. Concordance between upper and lower airway microbiota in infants with cystic fibrosis. Eur Respir J. 2017 Mar 29;49(3):1602235.
  15. Ren CL, Morgan RL, Oermann C, et al. Cystic Fibrosis Pulmonary Guidelines: Use of CFTR Modulator Therapy in Patients with Cystic Fibrosis. Ann Am Thorac Soc . 2018.